MARKET

GERN

GERN

Geron Corp
NASDAQ
2.080
-0.180
-7.96%
After Hours: 2.080 0 0.00% 16:02 03/04 EST
OPEN
2.260
PREV CLOSE
2.260
HIGH
2.278
LOW
2.070
VOLUME
8.16M
TURNOVER
0
52 WEEK HIGH
3.735
52 WEEK LOW
1.680
MARKET CAP
1.14B
P/E (TTM)
-6.4456
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Geron (GERN)
TipRanks · 13h ago
Weekly Report: what happened at GERN last week (0226-0301)?
Weekly Report · 16h ago
Geron Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Geron (NASDAQ:GERN) missed analyst estimates by 20%. Earnings per share exceeded estimates by 7.5%. The company's shares are up 2.0% from a week ago. Revenue is forecast to grow 46% p.a. On average during the next 3 years. Geron has three warning signs for investors.
Simply Wall St · 3d ago
Stifel Nicolaus Sticks to Its Buy Rating for Geron (GERN)
TipRanks · 4d ago
Buy Rating on Geron Corp. Anchored by Imetelstat’s FDA Approval Outlook and Favorable Safety Profile
TipRanks · 5d ago
Buy Rating Affirmed for Geron on Strong Cash Position and Positive Clinical Study Projections
TipRanks · 5d ago
Needham Reiterates Buy on Geron, Maintains $4 Price Target
Benzinga · 5d ago
Geron (GERN) Q4 2023 Earnings Call Transcript
Geron Corporation's fourth quarter and full-year 2023 earnings conference call will be held on February 28, 2024. Geron's imetelstat has a PDUFA date of June 16, 2024, for the treatment of transfusion-dependent lower-risk MDS. The company's management team will discuss the company's financial results.
The Motley Fool · 5d ago
More
About GERN
Geron Corporation is a late-stage biopharmaceutical company. The Company is focused on the development and commercialization of imetelstat, a therapeutic for hematologic malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13mer oligonucleotide that the Company designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Its lead indication for imetelstat is in low or intermediate-1 risk myelodysplastic syndromes (MDS). It is also engaged in the development of two indications, such as the treatment of adult patients with transfusion-dependent anemia due to lower risk MDS, and the treatment of adult patients with Intermediate-2 or High-Risk MF whose disease has relapsed after or is refractory to janus associate kinase inhibitor (JAK) inhibitor treatment.

Webull offers Geron Corp stock information, including NASDAQ: GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GERN stock methods without spending real money on the virtual paper trading platform.